COBRA PzF Coronary Stent System in Native Coronary Arteries for Early Healing, Thrombus Inhibition, Endothelialization, and Avoiding Long-Term Dual Anti-Platelet Therapy – The PzF SHIELD Trial

Completed · 2013 until 2021

Clinical Studies
Multicentric, KSSG as participating partner
Start Date
End Date
Study Design
Prospective, multi-center, non-randomized, single arm clinical trial, conducted at up to 40 sites in the United States and OUS. Enrolling 296 patients with symptomatic ischemic heart disease due to a single de novo lesion contained within a native coronary artery amenable to percutaneous coronary intervention (PCI) and stent deployment. Follow-up at 30 days, 6 months, 9 months, 1, 2, 3, 4 and 5 years post index stenting procedure.
Cobra, Stent, Medizinprodukt
Brief description/objective

The main objective of this study is to evaluate the safety and effectiveness of the COBRA PzF Coronary Stent System in the treatment of de novo lesions in native coronary arteries. The COBRA PzF Coronary Stent System is a balloon-expandable bare metal coronary stent with a nanothin surface treatment of novel Polyzene-F polymer on a low-profile rapid-exchange delivery system.

The primary endpoint will be the incidence of target vessel failure (TVF, see definition below) within 270 days of treatment with the COBRA PzF Coronary Stent System. This rate will be compared to a performance goal derived using a meta-analysis from published historical data of the standard-of-care therapy, coronary stenting with bare metal stents.